Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL (clinicaltrials.gov) - Oct 17, 2026 - P2 | N=38 | Recruiting | Sponsor: Shanghai Zhongshan Hospital | Not yet recruiting ➔ Recruiting | Trial completion date: Jul 2026 ➔ Jul 2027 | Trial primary completion date: Jul 2026 ➔ Mar 2027
Enrollment open • Trial completion date • Trial primary completion date • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin's Lymphoma • Oncology • CD20
|